Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 8/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31508108 | 0.79 | MAPK14 (0.33) | USP30TMPRSS15 | |
| SCHEMBL6496980 | 0.78 | HCAR2 (0.44) | USP30HCAR2ALDH1A1TMPRSS15CYP3A4 | |
| SCHEMBL31508275 | 0.77 | CISD2 (0.33) | USP30TMPRSS15 | |
| SCHEMBL19304047 | 0.69 | GBA1 (0.39) | ALDH1A1 | |
| SCHEMBL4038874 | 0.69 | ALDH1A1 (0.44) | USP30ALDH1A1TMPRSS15 | |
| SCHEMBL16529805 | 0.68 | MLYCD (0.40) | USP30ALDH1A1MLYCD | |
| SCHEMBL19304236 | 0.68 | P4HTM (0.41) | ALDH1A1 | |
| SCHEMBL19219153 | 0.68 | STK17B (0.36) | — | |
| SCHEMBL12097794 | 0.67 | GPBAR1 (0.39) | — | |
| SCHEMBL16526196 | 0.66 | ALDH1A1 (0.35) | USP30ALDH1A1MLYCDTMPRSS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | USP30 4768/4885HCAR2 2455/4885ALDH1A1 198/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | USP30 4768/4885HCAR2 2455/4885ALDH1A1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.